 |
 |
醫(yī)學論文范文:伊立替康聯合順鉑一線治療晚期非小細胞肺癌臨床觀察
【摘要】 目的 評價伊立替康(CPT-11)聯合順鉑(DDP)方案一線治療晚期非小細胞肺癌(NSCLC)的療效和不良反應。方法 經病理學或細胞學確診的初治晚期NSCLC患者35例，男20例，女15例，年齡35～60歲，KPS評分>70分。順鉑75 mg/m2第1～3天靜脈輸注，CPT-11 100 mg/m2第1、8天靜脈輸注，每3周重復1次，至少2周期以上可評價療效及不良反應。結果 全組 CR 1例(2.8%)，PR 10例 (28.6%)，SD 20例(57.1%)，PD 4例(11.4%)。整體客觀有效率為31.4%(11/35)，疾病控制率88.5%，中位治療至進展時間為199 d，1年生存率為54.3%(19/35),2年生存率為11.4%(4/35)。Ⅲ度和Ⅳ度不良反應的發(fā)生率為粒細胞減少17.1%，血小板減少2.8%，脫發(fā)17.1%，腹瀉8.6%，惡心、嘔吐2.8%。結論 CPT-11聯合DDP方案對晚期NSCLC治療有效，患者耐受性良好。
【關鍵詞】 伊立替康;順鉑;非小細胞肺癌;化學療法
Irinotecan in combination with cisplatin in the first-line
therapy for advanced NSCLC醫(yī).學全.在.線網站zxtf.net.cn
CHEN Yu, HE Zhiyong, LIN Dong
(The 12th Ward, Department of Internal Medicine, Fujian Provincial Tumor Hospital, Fuzhou, Fujian 350000, China)
Abstract:Objective To evaluate the efficacy of irinotecan (CPT-11) combined with cisplatin (DDP) in the first-line treatment of advanced NSCLC and the adverse reactions.Methods 35 patients diagnosed as having advanced NSCLC by pathology or cytology were enrolled, including 20 men and 15 women. The median age was 47 years, KPS score > 70. DDP was given at 75mg/m2 by intravenous infusion from day 1 to day 3, and CPT-11 was given at 100 mg/m2 by intravenous drip on day 1 and day 8, with the regimen given every 3 weeks for at least 2 cycles to assess the efficacy and possible adverse reaction.Results Totally, 114 cycles were carried out in these 35 patients with a medium cycles of 3. Of the 35 evaluable patients, there was 1 case (2.8%) of complete response (CR), 10 cases (28.6%) of partial response (PR), 20 cases (57.1%) of stable disease (SD) and 4 cases (11.4%) of progressive disease (PD), with an objective response rate of 31.4% (11/35) and a disease control rate of 88.5%. The median survival time was 199 days, the actual 1-year survival rate being 54.3% (19/35) and 2-year survival rate being 11.4% (4/35). The grade III/IV adverse events included neutropenia (17.1%), thrombocytopenia (2.8%), alopecia (17.1%), diarrhea (8.6%), nausea and vomiting (2.8%).Conclusion CPT-11 combined with DDP is effective in the treatment of advanced NSCLC with tolerable adverse events.
